Reprogramming of the MicroRNA Transcriptome Mediates Resistance to Rapamycin

Rapamycin Resistance Is Linked to Defective Regulation of Skp2

(2012) H. Totary-Jain et al.   CANCER RESEARCH

Cooperative control of tumor suppressor genes by a network of oncogenic microRNAs

(2011) Konstantinos J. Mavrakis et al.   CELL CYCLE

PI3K/AKT signaling determines a dynamic switch between distinct KSRP functions favoring skeletal myogenesis

(2011) P Briata et al.   CELL DEATH AND DIFFERENTIATION

MicroRNA let-7c Suppresses Androgen Receptor Expression and Activity via Regulation of Myc Expression in Prostate Cancer Cells

(2011) Nagalakshmi Nadiminty et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Transcriptome-wide Identification of RNA-Binding Protein and MicroRNA Target Sites by PAR-CLIP

(2010) Markus Hafner et al.   CELL

Thelet-7microRNA reduces tumor growth in mouse models of lung cancer

(2010) Aurora Esquela-Kerscher et al.   CELL CYCLE

The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF-β Pathway in Neuroblastoma

(2010) Pieter Mestdagh et al.   MOLECULAR CELL

Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein

(2010) J Xiong et al.   ONCOGENE

Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

(2009) Ryan J.O. Dowling et al.   BIODRUGS

MicroRNAs: new players in acute myeloid leukaemia

(2009) V Havelange et al.   BRITISH JOURNAL OF CANCER

MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through Eukaryotic Initiation Factor 4E-Binding Protein 1-Mediated Inhibition of Autophagy

(2009) B. S. Balakumaran et al.   CANCER RESEARCH

mTOR inhibitors for hepatocellular cancer: a forward-moving target

(2009) Gerhard Treiber   Expert Review of Anticancer Therapy

mTOR in renal cell cancer: modulator of tumor biology and therapeutic target

(2009) Piotr J Wysocki   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

miR-19 is a key oncogenic component of mir-17-92

(2009) V. Olive et al.   GENES & DEVELOPMENT

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma

(2009) Danit Lebanony et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

(2009) M. Breuleux et al.   MOLECULAR CANCER THERAPEUTICS

The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs

(2009) Michele Trabucchi et al.   NATURE

Everolimus

(2009) Michael B. Atkins et al.   NATURE REVIEWS DRUG DISCOVERY

Role of miR-143 targeting KRAS in colorectal tumorigenesis

(2009) X Chen et al.   ONCOGENE

Progress in the treatment of neuroendocrine tumors

(2009) Jennifer A. Chan et al.   Current Oncology Reports

MicroRNAs as biomarkers and therapeutic drugs in human cancer

(2008) M. Osaki et al.   BIOMARKERS

Microarray background correction: maximum likelihood estimation for the normal-exponential convolution

(2008) J. D. Silver et al.   BIOSTATISTICS

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

(2008) Monica Mita et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer

(2008) C. Gridelli et al.   ONCOLOGIST